RP9

Summary

RP9 (RP9 pre-mRNA splicing factor, HGNC:10288) is a protein-coding gene on chromosome 7p14.3, encoding Retinitis pigmentosa 9 protein (Q8TA86). Is thought to be a target protein for the PIM1 kinase.

The protein encoded by this gene can be bound and phosphorylated by the protooncogene PIM1 product, a serine/threonine protein kinase . This protein localizes in nuclear speckles containing the splicing factors, and has a role in pre-mRNA splicing. CBF1-interacting protein (CIR), a corepressor of CBF1, can also bind to this protein and effects alternative splicing. Mutations in this gene result in autosomal dominant retinitis pigmentosa-9. This gene has a pseudogene (GeneID: 441212), which is located in tandem array approximately 166 kb distal to this gene.

Source: NCBI Gene 6100 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa 9 (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 129 total — 1 likely-pathogenic
• Phenotypes (HPO): 38
• MANE Select transcript: NM_203288

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10288
Approved symbol	RP9
Name	RP9 pre-mRNA splicing factor
Location	7p14.3
Locus type	gene with protein product
Status	Approved
Aliases	PAP-1
Ensembl gene	ENSG00000164610
Ensembl biotype	protein_coding
OMIM	607331
Entrez	6100

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 3 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000297157, ENST00000448915, ENST00000474370, ENST00000492391, ENST00000682645, ENST00000683432, ENST00000684207

RefSeq mRNA: 1 — MANE Select: NM_203288 NM_203288

CCDS: CCDS5440

Canonical transcript exons

ENST00000297157 — 6 exons

Exon	Start	End
ENSE00001085942	33097271	33097362
ENSE00001180952	33109221	33109404
ENSE00001271164	33094797	33095432
ENSE00001653044	33099307	33099436
ENSE00001710380	33096493	33096554
ENSE00003519355	33100531	33100561

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 95.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.3416 / max 124.2666, expressed in 1778 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
83518	10.2216	1778
83517	0.1201	25

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	95.85	gold quality
left ventricle myocardium	UBERON:0006566	93.81	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.17	gold quality
secondary oocyte	CL:0000655	91.96	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.37	gold quality
apex of heart	UBERON:0002098	90.99	gold quality
gastrocnemius	UBERON:0001388	90.47	gold quality
muscle of leg	UBERON:0001383	90.34	gold quality
body of tongue	UBERON:0011876	90.26	gold quality
pylorus	UBERON:0001166	89.77	gold quality
sural nerve	UBERON:0015488	89.63	gold quality
heart left ventricle	UBERON:0002084	89.62	gold quality
skeletal muscle tissue	UBERON:0001134	89.48	gold quality
cardiac ventricle	UBERON:0002082	89.47	gold quality
quadriceps femoris	UBERON:0001377	89.16	gold quality
vastus lateralis	UBERON:0001379	89.16	gold quality
muscle tissue	UBERON:0002385	89.00	gold quality
tongue	UBERON:0001723	88.94	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.83	gold quality
cardia of stomach	UBERON:0001162	88.80	gold quality
cardiac atrium	UBERON:0002081	88.52	gold quality
deltoid	UBERON:0001476	88.50	gold quality
right atrium auricular region	UBERON:0006631	88.38	gold quality
thymus	UBERON:0002370	88.35	gold quality
superior surface of tongue	UBERON:0007371	88.32	gold quality
heart	UBERON:0000948	88.28	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.07	silver quality
spleen	UBERON:0002106	87.85	gold quality
body of pancreas	UBERON:0001150	87.80	gold quality
kidney epithelium	UBERON:0004819	87.78	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting RP9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-5587-5P	99.07	68.58	838
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-7114-3P	98.42	66.53	569
HSA-MIR-1233-5P	98.19	66.71	1201
HSA-MIR-6778-5P	98.19	66.59	1239
HSA-MIR-1180-5P	98.16	65.32	460
HSA-MIR-556-5P	97.75	66.17	473
HSA-MIR-6747-3P	97.73	64.84	1596
HSA-MIR-6849-3P	97.25	64.57	1371
HSA-MIR-212-5P	96.83	67.43	950
HSA-MIR-3189-3P	96.80	66.34	896
HSA-MIR-7973	96.48	65.54	502

Literature-anchored findings (GeneRIF, showing 4)

• Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa (PMID:12032732)
• Has a role in pre-mRNA splicing, further evidence that PAP-1 is indeed the RP9 gene. (PMID:15474994)
• PAP-1 interacted with Prp3p but not Prp31p in human cells and yeast, and the basic region of PAP-1 and the C-terminal region of Prp3p, regions beside spots found in retinitis pigmentosa mutations, were needed for binding (PMID:15541726)
• CIR was found to be colocalized with PAP-1 in nuclear speckles. (PMID:15652350)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rp9	ENSMUSG00000032239
rattus_norvegicus	Rp9	ENSRNOG00000029456

Protein

Protein identifiers

Retinitis pigmentosa 9 protein — Q8TA86 (reviewed: Q8TA86)

Alternative names: Pim-1-associated protein

All UniProt accessions (5): A0A090N8Z0, A0A804HI79, A0A804HL29, C9J6V2, Q8TA86

UniProt curated annotations — full annotation on UniProt →

Function. Is thought to be a target protein for the PIM1 kinase. May play some roles in B-cell proliferation in association with PIM1.

Subunit / interactions. Binds to PIM1. Binds to ZNHIT4.

Subcellular location. Nucleus.

Tissue specificity. Appears to be expressed in a wide range of tissues.

Disease relevance. Retinitis pigmentosa 9 (RP9) [MIM:180104] A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry.

RefSeq proteins (1): NP_976033* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR034585	PAP-1	Family

UniProt features (16 total): compositionally biased region 5, sequence variant 3, region of interest 3, modified residue 2, chain 1, zinc finger region 1, cross-link 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TA86-F1	78.99	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 212, 214, 129

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 149 (showing top): GOBP_COGNITION, INGRAM_SHH_TARGETS_UP, GOBP_RNA_SPLICING, GOCC_ROUGH_ENDOPLASMIC_RETICULUM, GOCC_ROUGH_ENDOPLASMIC_RETICULUM_MEMBRANE, ZHENG_BOUND_BY_FOXP3, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, VECCHI_GASTRIC_CANCER_EARLY_UP, BRUINS_UVC_RESPONSE_LATE, SUPT16H_TARGET_GENES, ZNF618_TARGET_GENES, MIR1253, GSE11864_UNTREATED_VS_CSF1_IFNG_PAM3CYS_IN_MAC_UP

GO Biological Process (2): RNA splicing (GO:0008380), cognition (GO:0050890)

GO Molecular Function (4): RNA binding (GO:0003723), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), signal recognition particle receptor complex (GO:0005785)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	1
nervous system process	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
rough endoplasmic reticulum membrane	1
membrane protein complex	1
endoplasmic reticulum protein-containing complex	1

Protein interactions and networks

STRING

652 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RP9	PRPF31	Q8WWY3	897
RP9	PRPF3	O43395	891
RP9	PRPF8	Q6P2Q9	862
RP9	FSCN2	O14926	849
RP9	SNRNP200	O75643	831
RP9	PRPH2	P23942	825
RP9	IMPDH1	P20839	809
RP9	TOPORS	Q9NS56	792
RP9	CERKL	Q49MI3	778
RP9	KLHL7	Q8IXQ5	760
RP9	GUCA1B	Q9UMX6	745
RP9	ROM1	Q03395	744
RP9	RPGR	Q92834	744
RP9	EYS	Q5T1H1	740
RP9	PCARE	A6NGG8	739

IntAct

89 interactions, top by confidence:

A	B	Type	Score
CAPN1	CAPNS1	psi-mi:“MI:0914”(association)	0.840
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CSNK2B	NMT2	psi-mi:“MI:0914”(association)	0.660
SUMO1	CBX4	psi-mi:“MI:0914”(association)	0.600
SREK1IP1	RP9	psi-mi:“MI:0915”(physical association)	0.560
SDCBP	RP9	psi-mi:“MI:0915”(physical association)	0.560
NKAPD1	RP9	psi-mi:“MI:0915”(physical association)	0.560
FGF12	RP9	psi-mi:“MI:0915”(physical association)	0.560
RP9	MMTAG2	psi-mi:“MI:0915”(physical association)	0.560
BYSL	RP9	psi-mi:“MI:0915”(physical association)	0.560
AP1M1	RP9	psi-mi:“MI:0915”(physical association)	0.560
USP54	DYRK1A	psi-mi:“MI:0914”(association)	0.550
EZH1	EPOP	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
SRSF1	RP9	psi-mi:“MI:0403”(colocalization)	0.450
OTUB1		psi-mi:“MI:0914”(association)	0.350
PPP2CA	DKFZP586J0619	psi-mi:“MI:0914”(association)	0.350
OFD1	SUPT5H	psi-mi:“MI:0914”(association)	0.350
RIPK1	TAF4	psi-mi:“MI:0914”(association)	0.350
DUSP6	HSPB1	psi-mi:“MI:0914”(association)	0.350
LCK	UQCRQ	psi-mi:“MI:0914”(association)	0.350
FYN	MRPS12	psi-mi:“MI:0914”(association)	0.350
SLC16A11	ESYT2	psi-mi:“MI:0914”(association)	0.350
POC5	PDHX	psi-mi:“MI:0914”(association)	0.350
RP9	C1orf226	psi-mi:“MI:0914”(association)	0.350
JPH3	PLEKHG3	psi-mi:“MI:0914”(association)	0.350

BioGRID (113): RP9 (Affinity Capture-MS), RP9 (Affinity Capture-MS), RP9 (Affinity Capture-MS), RP9 (Affinity Capture-MS), RP9 (Affinity Capture-MS), RP9 (Two-hybrid), U2AF1 (Reconstituted Complex), U2AF1 (Affinity Capture-Western), RP9 (Affinity Capture-MS), RP9 (Affinity Capture-MS), RP9 (Affinity Capture-MS), RP9 (Two-hybrid), RP9 (Two-hybrid), RP9 (Two-hybrid), RP9 (Two-hybrid)

ESM2 similar proteins: A2AQ19, B2GV05, O54941, O55047, O95232, P08621, P09406, P23588, P50502, P52756, P97762, Q07866, Q08CW1, Q13123, Q1ECX4, Q1RMR2, Q1RMU5, Q32KT0, Q3SX41, Q56A18, Q5NVI3, Q5R8W6, Q5RAD5, Q5RF31, Q5SRX1, Q5SUF2, Q5U2T8, Q5U2U0, Q5ZI03, Q62376, Q66HG8, Q66II8, Q6PH81, Q7TNC4, Q86UE8, Q86X95, Q8BGD9, Q8C0V0, Q8TA86, Q90ZY6

Diamond homologs: P97762, Q8TA86, Q8VZ67

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PIM1	unknown	RP9	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

129 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	73
Likely benign	35
Benign	9

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3340512	NM_203288.2(RP9):c.484_485del (p.Gln162fs)	Likely pathogenic

SpliceAI

781 predictions. Top by Δscore:

Variant	Effect	Δscore
7:33095429:TATC:T	acceptor_gain	1.0000
7:33095431:TC:T	acceptor_gain	1.0000
7:33095432:CC:C	acceptor_gain	1.0000
7:33095432:CCT:C	acceptor_loss	1.0000
7:33095433:C:CC	acceptor_gain	1.0000
7:33095439:A:AC	acceptor_gain	1.0000
7:33095439:A:C	acceptor_gain	1.0000
7:33095442:C:CT	acceptor_gain	1.0000
7:33095443:A:T	acceptor_gain	1.0000
7:33096488:CTCA:C	donor_loss	1.0000
7:33096489:TCA:T	donor_loss	1.0000
7:33096496:ACGT:A	donor_gain	1.0000
7:33096497:CGTC:C	donor_gain	1.0000
7:33096499:T:TA	donor_gain	1.0000
7:33096556:T:C	acceptor_gain	1.0000
7:33096564:C:CT	acceptor_gain	1.0000
7:33097267:TTA:T	donor_loss	1.0000
7:33097268:TA:T	donor_loss	1.0000
7:33097269:A:AC	donor_gain	1.0000
7:33097269:A:C	donor_loss	1.0000
7:33097269:AC:A	donor_gain	1.0000
7:33097270:C:CC	donor_gain	1.0000
7:33097270:CC:C	donor_gain	1.0000
7:33097270:CCA:C	donor_gain	1.0000
7:33097270:CCACT:C	donor_gain	1.0000
7:33097358:CCAAC:C	acceptor_gain	1.0000
7:33097359:CAAC:C	acceptor_gain	1.0000
7:33097359:CAACC:C	acceptor_gain	1.0000
7:33097360:AAC:A	acceptor_gain	1.0000
7:33097361:AC:A	acceptor_gain	1.0000

AlphaMissense

1458 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:33097277:G:C	F133L	1.000
7:33097277:G:T	F133L	1.000
7:33097279:A:G	F133L	1.000
7:33097317:C:G	C120S	1.000
7:33097318:A:G	C120R	1.000
7:33097318:A:T	C120S	1.000
7:33097337:G:C	H113Q	1.000
7:33097337:G:T	H113Q	1.000
7:33097339:G:C	H113D	1.000
7:33097341:C:T	G112D	1.000
7:33097353:C:G	C108S	1.000
7:33097354:A:G	C108R	1.000
7:33097354:A:T	C108S	1.000
7:33097358:C:A	W106C	1.000
7:33097358:C:G	W106C	1.000
7:33097360:A:G	W106R	1.000
7:33097360:A:T	W106R	1.000
7:33099307:A:G	C105R	1.000
7:33099371:A:C	F83L	1.000
7:33099371:A:T	F83L	1.000
7:33099372:A:G	F83S	1.000
7:33099373:A:G	F83L	1.000
7:33099408:A:T	I71K	1.000
7:33095421:A:G	L160S	0.999
7:33096543:A:C	D139E	0.999
7:33096543:A:T	D139E	0.999
7:33096544:T:C	D139G	0.999
7:33096544:T:G	D139A	0.999
7:33096551:G:C	H137D	0.999
7:33097274:T:A	R134S	0.999

dbSNP variants (sampled 300 via entrez): RS1000086794 (7:33105826 A>G,T), RS1000169028 (7:33094322 G>T), RS1000514907 (7:33105284 A>C), RS1000568647 (7:33110534 T>C), RS1001623936 (7:33097582 A>G), RS1001665760 (7:33110863 C>T), RS1001786135 (7:33103714 T>C), RS1001899174 (7:33102476 T>G), RS1001956091 (7:33095677 A>G), RS1001965211 (7:33104066 T>G), RS1002225011 (7:33108871 C>T), RS1002521526 (7:33102146 A>G), RS1002731619 (7:33104437 A>AG), RS1002786165 (7:33096632 GA>G), RS1003075212 (7:33096040 C>G)

Disease associations

OMIM: gene MIM:607331 | disease phenotypes: MIM:180104, MIM:268000

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa 9	Strong	Autosomal dominant
retinitis pigmentosa	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
retinitis pigmentosa 9	Limited	AD

Mondo (4): retinitis pigmentosa 9 (MONDO:0008378), inherited retinal dystrophy (MONDO:0019118), retinitis pigmentosa (MONDO:0019200), optic atrophy (MONDO:0003608)

Orphanet (2): Retinitis pigmentosa (Orphanet:791), OBSOLETE: Inherited retinal disorder (Orphanet:71862)

HPO phenotypes

38 total (30 of 38 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000405	Conductive hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000501	Glaucoma
HP:0000505	Visual impairment
HP:0000510	Rod-cone dystrophy
HP:0000512	Abnormal electroretinogram
HP:0000518	Cataract
HP:0000543	Optic disc pallor
HP:0000546	Retinal degeneration
HP:0000551	Color vision defect
HP:0000563	Keratoconus
HP:0000602	Ophthalmoplegia
HP:0000613	Photophobia
HP:0000618	Blindness
HP:0000639	Nystagmus
HP:0000648	Optic atrophy
HP:0000662	Nyctalopia
HP:0000842	Hyperinsulinemia
HP:0001105	Retinal atrophy
HP:0001133	Constriction of peripheral visual field
HP:0007401	Macular atrophy
HP:0007663	Reduced visual acuity
HP:0007675	Progressive night blindness
HP:0007688	Undetectable light- and dark-adapted electroretinogram
HP:0007703	Abnormal retinal pigmentation
HP:0007737	Spicular pigmentation of the retina
HP:0007787	Posterior subcapsular cataract
HP:0007843	Attenuation of retinal blood vessels
HP:0007994	Peripheral visual field loss

GWAS associations

0 associations (top):

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D009896	Optic Atrophy	C10.292.700.225; C11.640.451
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684
C566716	Retinitis Pigmentosa 9 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, increases abundance, increases expression	2
Cisplatin	decreases expression, increases expression, affects cotreatment	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
methylmercuric chloride	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Leflunomide	increases expression	1
Caffeine	decreases phosphorylation	1
Ethyl Methanesulfonate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Phenobarbital	affects expression	1
Silicon Dioxide	increases expression	1
T-2 Toxin	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tunicamycin	increases expression	1
Cyclosporine	increases expression	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

7 cell lines: 7 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_QX20	K10M15	Induced pluripotent stem cell	Male
CVCL_T830	K10M17	Induced pluripotent stem cell	Male
CVCL_T831	K10M19	Induced pluripotent stem cell	Male
CVCL_T832	K10M5	Induced pluripotent stem cell	Male
CVCL_T833	K11M4	Induced pluripotent stem cell	Female
CVCL_T834	K11PD17	Induced pluripotent stem cell	Female
CVCL_T835	K11PD18	Induced pluripotent stem cell	Female

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa